Message Font: Serif | Sans-Serif
No. of Recommendations: 1
But bottom line, those guys own a heck of alot more Aurora stock than I do, and are getting the same .62 shares of VRTX.

I agree with your sentiment.

One can make the arguement that both companies benefit from the merger, and are undervalued.

ABSC no longer needs to struggle to fight alone to get to end targets that lead to higher return: drugs that can make it through the process. Thus, ABSC can perfect its technology and Big Biology programs to maximize their value to VRTX. VRTX brings to the table multiple target opportunities to use the ABSC platform. The synergy here lets ABSC not have to potentially waste a bunch of money seeking targets. The royalties to be derived from drug discovery by those other pharmaceutical companies that utilize ABSC screening technology are also still out there, not yet accounted for.

VRTX has a pipeline which, if successfully mined, brings huge opportunity to the table. One which ABSC could not match alone in any easy fashion.

Interesting combined company.

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.